Description  Claims  Drawing  Cited references 

WO0136403A1   [0007] 
EP1402888A1   [0008] 
WO2004080950A1   [0009] 
WO2004082677A1   [0010] 
WO2007124423A1   [0011] 
WO2010036316A1   [0012] 

Positron Emission Tomography and Single-Photon Emission Computed Tomography in Central Nervous System Drug Development   [0067] 
Pharmaceutical Salts   [0071] 
Design of Prodrugs   [0074] 
J. Med. Chem.   [0075] 
J. Pharm. Sci.   [0075] 
Drug Dev. Res.   [0075] 
Adv. Drug Res.   [0075] 
Design of Prodrugs   [0075] 
Design and Application of Prodrugs, Drug Design and Development   [0075] 
Angew. Chem. Int. Ed. Eng.   [0099] 
J. Org. Chem.   [0100] 
Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein   [0152] 
beta-Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor   [0152] 
Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders   [0152] 
Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters   [0152]